8-K: Vivani Medical Announces Positive Preclinical Results for GLP-1 Implant, Clinical Trials on Track

Vivani Medical's GLP-1 implant demonstrated an 82% reduction in liver fat in preclinical studies, with clinical trials for their obesity program expected to begin in the fourth quarter of 2024.

Summary

• Vivani Medical announced positive preclinical results for their GLP-1 (exenatide) implant, showing an 82% reduction in liver fat in an obese mouse model.
• This reduction was achieved with a single administration of the implant, suggesting a potential for twice-yearly dosing.
• The company previously reported a 20% weight loss with the same implant in preclinical studies, comparable to results seen with semaglutide (Ozempic/Wegovy).
• Clinical development of the exenatide implant for overweight and obese patients, as part of the NPM-115 program, is on track to commence in the fourth quarter of 2024.
• The first clinical study, LIBERATE-1, is anticipated to start in the fourth quarter of 2024 with results expected in 2025.
• The LIBERATE-1 study will involve an initial eight-week titration on semaglutide, followed by randomization to receive either the exenatide implant, weekly exenatide injections, or weekly semaglutide injections for a nine-week treatment period.
• Vivani is also developing NPM-139, a semaglutide implant with the potential for once-yearly administration, and NPM-119, an exenatide implant for type 2 diabetes.

Sentiment

Score: 8

Explanation: The document presents very positive preclinical results and a clear path forward for clinical trials. The comparison to semaglutide is also a strong positive. However, the company is still in the development phase and has a history of losses, which tempers the overall sentiment.

Positives

• The 82% reduction in liver fat is a significant positive result from preclinical studies.
• The 20% weight loss achieved is comparable to the weight loss seen with semaglutide, a leading treatment.
• The twice-yearly dosing potential of the implant offers a significant advantage in terms of patient convenience.
• The company's focus on improving medication adherence and tolerability addresses key challenges with current GLP-1 treatments.
• The clinical trial program is progressing as planned, with the first study expected to start in the fourth quarter of 2024.

Negatives

• The results are from preclinical studies in mice, and human trials are needed to confirm these findings.
• The company is still in the development phase and has a history of losses.
• There are risks associated with the development and commercialization of the company's products.
• The company's ability to access additional capital is a potential risk.

Risks

• The development and commercialization of Vivani's products, including NPM-115, NPM-139, and NPM-119, are subject to risks.
• Delays and changes in the development of Vivani's products could occur due to applicable laws, regulations, and guidelines.
• There are potential delays in submitting and receiving regulatory clearance or approval to conduct Vivani's development activities.
• The initiation, enrollment, and conduct of Vivani's planned clinical trials and the results therefrom are subject to risks.
• Vivani has a history of losses and may face challenges in accessing additional capital to fund its business.

Future Outlook

Vivani anticipates initiating the LIBERATE-1 clinical trial in the fourth quarter of 2024 and expects to report results in 2025. The company is also focused on developing its pipeline of GLP-1 implants for obesity and type 2 diabetes.

Management Comments

• Adam Mendelsohn, Ph.D., Vivani President and Chief Executive Officer, stated that the reduction in liver fat provides further support that the NanoPortal implant technology holds great potential as a highly differentiated treatment option.
• Management believes that their implants' minimally fluctuating release profile combined with avoiding drug fluctuations from poor adherence may improve treatment tolerability.

Industry Context

The announcement comes amid a growing interest in GLP-1 based therapies for obesity and diabetes. Vivani's approach of using long-acting implants aims to address the challenges of medication adherence and tolerability that are often associated with current GLP-1 treatments, such as injections.

Comparison to Industry Standards

• The 82% reduction in liver fat is consistent with published results from similar investigations with semaglutide, the active ingredient in Ozempic and Wegovy.
• The 20% weight loss observed in preclinical studies is comparable to the weight loss produced by semaglutide in the same study.
• The company is directly comparing their results to semaglutide, a leading treatment in the market, indicating a competitive approach.
• The focus on long-acting implants differentiates Vivani from companies that primarily offer injectable or oral GLP-1 medications.

Stakeholder Impact

• Shareholders may view the positive preclinical results as a positive sign for the company's future.
• Employees may be encouraged by the progress of the company's clinical programs.
• Patients may be hopeful for new treatment options for obesity and diabetes.
• The company's success could potentially impact competitors in the GLP-1 market.

Next Steps

• Initiation of the LIBERATE-1 clinical trial in the fourth quarter of 2024.
• Enrollment of participants in the LIBERATE-1 study.
• Reporting of results from the LIBERATE-1 study in 2025.
• Continued development of NPM-139 (semaglutide implant) and NPM-119 (exenatide implant for type 2 diabetes).

Key Dates

Keywords

GLP-1 implant, exenatide, obesity, weight management, liver fat reduction, semaglutide, clinical trials, NPM-115, NanoPortal, medication adherence